Ozone-Induced Macrophage Efferocytosis: Mechanistic Insights for Neuropathic Pain Relief

Study Background and Research Question

Neuropathic pain (NPP) is a chronic, often intractable syndrome resulting from nerve injury or disease, affecting an estimated 7%–10% of the population and presenting a significant clinical challenge due to limited treatment efficacy and prominent side effects of current pharmacological options. Central to the pathogenesis of NPP is the persistent accumulation of apoptotic cells and the perpetuation of neuroinflammation, which together drive heightened pain sensitivity and tissue dysfunction. The reference study by Ruan et al. (2024) addresses a critical knowledge gap: Can targeted modulation of apoptotic cell clearance by macrophages (efferocytosis) offer a viable therapeutic route for NPP?

Key Innovation from the Reference Study

The reference work's innovation lies in dissecting how ozone therapy—administered at carefully titrated concentrations—enhances the efferocytic function of bone marrow-derived macrophages (BMDMs), thereby reducing neuroinflammation and neuropathic pain. Crucially, the study elucidates the mechanistic pathway: ozone activates AMP-activated protein kinase (AMPK), upregulates the bridging molecule Gas6, stimulates MerTK receptor signaling, and increases suppressor of cytokine signaling 3 (SOCS3) expression. This coordinated pathway orchestrates both apoptotic cell clearance and the suppression of key proinflammatory cytokines (IL-1β, IL-6, TNF-α), providing a multi-node intervention strategy for NPP.

Methods and Experimental Design Insights

The researchers employed a robust combination of in vivo and in vitro models:

• Neuropathic pain was induced in mice using a chronic constriction injury (CCI) model, a well-established paradigm for studying peripheral nerve injury and ensuing pain hypersensitivity.
• Ozone was administered at gradient concentrations (15, 30, 45 mg) to determine optimal efficacy and dose responsiveness.
• BMDMs were isolated and exposed to apoptotic neutrophils in vitro, allowing quantitative assessment of phagocytic (efferocytic) capacity post-ozone treatment.
• Mechanistic interrogation involved pharmacological inhibitors of AMPK (compound C) and MerTK (UNC2541), enabling the authors to confirm pathway specificity.
• Gene and protein expression analyses (e.g., for Gas6, SOCS3, inflammatory cytokines) were performed to map downstream molecular events.
• Pain behavior was measured using mechanical hypersensitivity assays, providing functional correlates to cellular and molecular changes.

Importantly, the study design integrated both pathway activation and functional outcome metrics, strengthening the causative narrative between efferocytosis and pain relief.

Core Findings and Why They Matter

The study's main findings are as follows:

• Ozone at 30 mg significantly reduced mechanical hypersensitivity in CCI mice, suggesting an optimal therapeutic window.
• Ozone treatment upregulated the phagocytic activity of BMDMs toward apoptotic neutrophils, directly addressing the problem of impaired efferocytosis in NPP.
• Mechanistically, ozone activated AMPK, selectively increased Gas6 (but not Protein S), stimulated MerTK receptor signaling, and upregulated SOCS3—culminating in reduced expression of proinflammatory mediators.
• Pharmacological blockade of AMPK or MerTK abrogated the beneficial effects of ozone, confirming the centrality of this signaling axis.

These findings matter because they bridge a crucial gap between immune cell function and pain regulation, highlighting efferocytosis as both a mechanistic and therapeutic target. As the authors note, the abolition of ozone's effects by pathway-specific inhibitors strengthens the translational relevance of these molecular nodes for future drug development.

Comparison with Existing Internal Articles

While this study primarily focuses on immune signaling and pain, it intersects with the broader field of microenvironmental regulation—a theme explored in several internal articles about pH dynamics and probe technologies:

• The article "Transforming Microenvironmental pH Sensing in Translational Research" discusses how advanced fluorescent pH probes, such as BCECF (2',7'-bis(carboxyethyl)-5(6)-Carboxyfluorescein), enable precise measurement of extracellular acid-base shifts, which are often coupled to immune cell activation and apoptosis in disease models—including neuropathic pain.
• "BCECF in Microenvironmental pH Assays: Precision for Pathophysiology" specifically addresses the design of microenvironmental pH regulation assays, which are highly relevant for dissecting the metabolic and signaling landscapes underpinning efferocytosis and cytokine release.
• Other resources, such as "BCECF (2',7'-bis(carboxyethyl)-5(6)-Carboxyfluorescein): A Reliable Ratiometric pH Probe", provide methodological guidance for researchers interested in coupling pH-sensitive fluorescent dyes to studies of ion transport, cellular metabolism, and acid-base homeostasis—complementing the immune and pain research highlighted in the reference study.

Collectively, these articles underscore how probing microenvironmental pH, for example with a fluorescent pH probe for ion transport studies, can synergize with immune signaling investigations to offer a multidimensional understanding of disease mechanisms.

Limitations and Transferability

Despite its strengths, the reference study has several limitations:

• All experiments were conducted in murine models; human translation requires further validation, especially given species-specific differences in immune regulation and pain perception.
• The ozone concentrations and exposure protocols need careful adaptation for clinical or alternative preclinical settings to ensure both efficacy and safety.
• The study focused on a narrow set of inflammatory mediators; broader cytokine or metabolic profiling could reveal additional mechanistic layers.
• Potential off-target effects of ozone or inhibitors were not extensively characterized, warranting further pharmacological investigation.

That said, the clear demonstration that enhancing macrophage efferocytosis modulates pain opens the door for applying these findings to other contexts of chronic inflammation, tissue injury, and immune dysregulation, although direct transfer to human clinical practice remains preliminary.

Protocol Parameters

• Ozone administration: 30 mg shown to be optimal in CCI mouse model for reducing pain and enhancing macrophage efferocytosis; use titration to confirm optimal dose in new systems.
• AMPK/MerTK pathway interrogation: Use AMPK inhibitor (e.g., compound C) and MerTK inhibitor (UNC2541) to validate mechanistic dependence in efferocytosis assays.
• BMDM efferocytosis assay: Co-culture ozone-treated BMDMs with apoptotic neutrophils; quantify phagocytic index via microscopy or flow cytometry.
• Pain behavior assessment: Employ von Frey or similar assays to measure mechanical hypersensitivity in parallel with molecular readouts.
• pH microenvironment monitoring (workflow suggestion): For studies linking efferocytosis, immune activation, and metabolic status, consider integrating a probe for cellular metabolism pH monitoring, such as BCECF, to track dynamic acid-base changes during immune response assays.

Research Support Resources

For researchers aiming to extend these findings or adapt similar immune-metabolic workflows, BCECF (2',7'-bis(carboxyethyl)-5(6)-Carboxyfluorescein) (SKU C5694) from APExBIO offers a robust, membrane-impermeant, ratiometric pH indicator suitable for quantitative extracellular or compartmental pH measurement. As detailed in recent literature, including guides to microenvironmental pH regulation assays, BCECF can be integrated into studies of acid-base homeostasis, transporter activity, and immune-metabolic cross-talk, providing an analytical foundation for interrogating the complex microenvironmental shifts that underpin efferocytosis and inflammation in neuropathic pain and related models.